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Escherichia coli B2 strains prevalent in
inflammatory bowel disease patients have
distinct metabolic capabilities that enable
colonization of intestinal mucosa
Xin Fang1, Jonathan M. Monk1, Nathan Mih1,2, Bin Du1, Anand V. Sastry1, Erol Kavvas1, Yara Seif1,
Larry Smarr3,4 and Bernhard O. Palsson1,5,6*
Abstract
Background: Escherichia coli is considered a leading bacterial trigger of inflammatory bowel disease (IBD). E. coli
isolates from IBD patients primarily belong to phylogroup B2. Previous studies have focused on broad comparative
genomic analysis of E. coli B2 isolates, and identified virulence factors that allow B2 strains to reside within human
intestinal mucosa. Metabolic capabilities of E. coli strains have been shown to be related to their colonization site, but
remain unexplored in IBD-associated strains.
Results: In this study, we utilized pan-genome analysis and genome-scale models (GEMs) of metabolism to study
metabolic capabilities of IBD-associated E. coli B2 strains. The study yielded three results: i) Pan-genome analysis of 110
E. coli strains (including 53 isolates from IBD studies) revealed discriminating metabolic genes between B2 strains and
other strains; ii) Both comparative genomic analysis and GEMs suggested that B2 strains have an advantage in
degrading and utilizing sugars derived from mucus glycan, and iii) GEMs revealed distinct metabolic features in B2
strains that potentially allow them to utilize energy more efficiently. For example, B2 strains lack the enzymes to
degrade amadori products, but instead rely on neighboring bacteria to convert these substrates into a more readily
usable and potentially less sought after product.
Conclusions: Taken together, these results suggest that the metabolic capabilities of B2 strains vary significantly
from those of other strains, enabling B2 strains to colonize intestinal mucosa.The results from this study motivate a
broad experimental assessment of the nutritional effects on E. coli B2 pathophysiology in IBD patients.
Keywords: Metabolic modeling, Pan-genome analysis, Inflammatory bowel disease
Background
Alteration of the composition of the gut microbial com-
munity has been implicated in inflammatory bowel
disease (IBD) [1]. Several studies have shown that the
abundance of E. coli in the gut microbiome of IBD
patients is higher compared to healthy subjects [1–3].
In comparison with healthy controls, E. coli isolates
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from IBD patients mainly belong to B2 and D phy-
logroups, including extraintestinal pathogenic E. coli
strains (ExPEC) [4]. In particular, a specific E. coli
pathotype, adherent-invasive E. coli (AIEC), has been
shown to be a leading bacterial trigger of IBD [5].
AIEC strains mostly belong to B2 phylogroups [3]. They
are able to adhere to intestinal epithelial cells and sur-
vive and replicate within macrophages, yet the spe-
cific genetic determinants of this pathotype are still
unknown [6].
In recent years, several comparative studies were per-
formed on E. coli isolates to understand their pathogenic-
ity in IBD [6–8]. Additionally, a few specific E. coli strains
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associated with IBD have been characterized in detail,
including LF82 [9], UM146 [10], and NRG857c [11], all of
which are in phylogroup B2. Most of these studies have
focused on comparative phenotypic assays and genome
analysis such as virulence factor determination. A previ-
ous study has shown that strains in B2 phylogroup pos-
sess certain virulence factors including adherence genes,
that allow them to persist within the human intestine,
while strains in A and B1 phylogroups are primarily tran-
sient E. coli strains [12]. However, the systems biology
of IBD-related E. coli strains, such as metabolic network
reconstructions that elucidate nutrient niches, remains
unexplored.
Genome-scale models (GEMs) represent a mathemat-
ical framework that enables a mechanistic description
of metabolic functions and how they relate to physio-
logical properties. GEMs have been used extensively to
contextualize multi-omics data as well as to understand
the genetic basis of phenotypic functions [13–16]. The
metabolism of E. coli strains has been studied extensively,
enabling the development of GEMs for a wide range of
E. coli strains. Recent studies have shown that strain-
specific GEMs are necessary to capture the variation in
metabolic capabilities in different strains [17], as the E.
coli pan-genome is estimated to have more than 45,000
genes [18].
In this study, we analyzed the metabolic capabilities
of B2 E. coli strains prevalent in IBD patients using
pan-genome analysis and genome-scale metabolic mod-
els. We look at a large set of E. coli strains from IBD
patients and healthy controls, as well as strains from
other origins, to see if we could identify any common
metabolic patterns associated with IBD pathophysiology
in B2 strains. We showed that specific metabolic capa-
bilities of the B2 group allow them to colonize intesti-
nal mucus and become resident E. coli strains in the
human gut.
Results
Strain collection studied
We collected available genomes of E. coli isolates from
previous IBD studies - 53 E. coli strains (22 AIEC, 31
non-AIEC), most of which were isolated from intesti-
nal biopsies of both IBD patients and healthy subjects
(see Additional file 1: Table S1). 52 of the 53 strains
belong to B2 groups; however these studies did not
include many genome sequences in other phylogroups
from healthy controls [6]. Thus, we set out to com-
pare these isolates with 57 other E. coli strains includ-
ing commensal strains and those that exhibit extra-
intestinal and intra-intestinal (InPEC) pathotypes. Of the
57 other E. coli strains, 14 strains belong to phylogroup
B2, and the other strains span various phylogroups
(see Additional file 2: Figure S1).
Strains in B2 phylogroup contain distinct metabolic genes
compared to strains in other phylogroups
To identify important metabolic features in B2 E. coli
strains, we first constructed the pan-genome from the
110 strains, including 53 strains isolated from both IBD
patients and healthy controls. A pan-genome for the 110
strains was built using CD-HIT [19] with 80% similarity
setting (see “Methods” section). We found an open pan
genome with 16,091 orthologous genes (see Additional
file 2: Figure S2), among which 2979 are metabolic genes
annotated by Enzyme Commission (EC) numbers. Out of
all the metabolic genes identified, only 1081 clusters are
conserved across 110 strains.We then further investigated
the distribution of the 1898 accessory metabolic genes in
110 strains.
We found that most B2 strains have distinct metabolic
genes compared to strains in other phylogroups (Fig. 1a).
Metabolic genes highlighted in the red box in Fig. 1a
are missing from most B2 strains, while genes high-
lighted by the orange box are more prevalent in B2 strains
(present in < 15% non-B2 strains and > 80% B2 strains).
We then selected the 100 most differentiating metabolic
genes between B2 strains and strains in other phylogroups
using the SelectKBest function from scikit-learn package
[20] (see “Methods” section). Of the selected genes, 53
genes are more prevalent in B2 strains and encode var-
ious functions including energy production, amino acid
metabolism, carbohydrate metabolism, and metal bind-
ing. GO enrichment analysis [21] suggested that these
genes are only enriched for tricarboxylic acid (TCA) cycle
(False discovery rate (FDR) adjusted p-value = 3.89 ×
10−2). Upon further investigation, we found that B2
strains possess an extra set of sucABCD genes that share
∼ 50% sequence identity with the original sucABCD genes
present in all strains. These four genes encode the impor-
tant enzymes in the TCA cycle: alpha-ketoglutarate dehy-
drogenase (sucAB) and succinyl coenzyme A synthetase
(sucCD) [22]. Experiments are needed to characterize the
function and importance of these gene variants in B2
strains. The remaining 47 metabolic genes that are pri-
marily absent from B2 strains are enriched for folic acid
catabolism (FDR adjusted p-value = 4.52 × 10−2), 3-
phenylpropionate catabolism (FDR adjusted p-value =
7.65 × 10−4) and putrescine catabolism (FDR adjusted
p-value = 1.97 × 10−3). To explore the relationship
between the metabolic functions and nutrient niches, we
further investigated specific metabolic genes.
IBD isolates and other ExPEC strains in the B2 phylogroup
contain uniquemetabolic genes that enable them to
utilize mucus glycan
We focused on elucidating the metabolic genes that allow
E. coli strains of the B2 group to reside within intesti-
nal mucosa. Glycans of the intestinal mucus can be
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Fig. 1 Pan-genome analysis shows B2 strains contain distinct metabolic genes. a 110 strains are clustered by the presence/absence of 1898
accessory metabolic genes. Genes in the red box are primarily absent from B2 strains, while genes in the orange box are more prevalent in B2
strains. b Presence and absence of genes involved in mucus degradation in 110 E. coli strains (genes are colored based on their functions in
monosaccharides degradation). The four highlighted genes annotated as tagatose bisphosphate (TBP) aldolase are more prevalent in B2 strains. c
Metabolic pathways of degradation of five nutrient sources involve TBP aldolase
utilized as a source of carbon and energy by intesti-
nal microbiota, and depletion of mucus is associated
with Crohn’s disease [23]. Research has shown that
commensals are mostly involved in cleavage of glycans
into monosaccharides, while pathogens such as E. coli
utilize the five monosaccharides released by commen-
sals: fucose, galactose, N-acetylgalactosamine (GalNAc),
N-acetylglucosamine (GlcNAc), and N-acetylneuraminic
acid (Neu5Ac) [24]. Therefore, we performed compara-
tive analysis on 48 genes (see Additional file 1: Table S2)
involved in mucus degradation among the 110 strains.
These genes were identified from a previous study
on degradation of mucin glycans [24] (see “Methods”
section). The resulting heatmap (Fig. 1b) illustrated that
although many genes have similar distribution among all
110 strains, four genes that are involved in tagatose 1,6-
bisphosphate (TBP) aldolase are more prevalent in the
B2 phylogroup (highlighted in Fig. 1b). These genes are
also present in a few D strains (see Additional file 2:
Figure S3), which was expected since both B2 and D
strains are commonly found in IBD patients [4]. TBP
aldolase converts TBP to dihydroxyacetone phosphate
and glyceraldehyde-3-phosphate that is subsequently fed
into central metabolism (Fig. 1c). Two of the four genes
are identified to be variants of known TBP aldolase sub-
unit GatY, while the other two genes are annotated to be
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TBP aldolase and related Type B Class II aldolases, but
have not been well-characterized.
We then performed structural analysis to confirm the
substrates and functions of the four genes annotated as
TBP aldolases. We obtained homology models for the
four proteins and compared them against the crystallized
structure of the known TBP aldolase [25] and fructose-
1,6-bisphosphate (FBP) aldolase [26], since these two
enzymes are highly similar. The models were found to
be more structurally similar to the known TBP aldolase,
rather than the FBP aldolase. This conclusion mainly
arose due to an extended sequence of amino acids in
FBP aldolase compared to TBP aldolase. This sequence
extends the α10 loop - α11 arm [25] that results in
the main differentiating feature between the enzymes’
monomer subunits. Additionally, differences in the sub-
strate binding sites lead to steric restrictions in FBP
aldolase that constrain its substrate to be highly specific
for FBP. All four predicted TBP aldolases contain differ-
ent sets of residues, suggesting that they have the potential
to greatly alter these steric restrictions and allow a wider
range of substrates (including TBP) to enter the binding
site. These differences are outlined in Additional file 2.
The presence of these additional TBP aldolases poten-
tially gives B2 strains an advantage to thrive in intestinal
mucosa, as TBP aldolase is an important enzyme that is
involved in the degradation of GalNAc and its derivatives
[24], as well as galactitol (Fig. 1c). These B2 strains are
likely to be more efficient in breaking down these nutri-
ent sources produced from mucus glycan, thus having
an advantage to survive in intestinal mucosa. Based on
these observations of differentiating metabolic features,
we next utilized genome-scalemodels to obtain a systems-
level understanding of themetabolic capabilities of B2 and
other strains.
Reconstruction of draft genome-scale metabolic models
for 110 strains
GEMs can be used to systematically determine the
metabolic capabilities of a strain [14]. We built GEMs
of the 110 strains by mapping their genomes to a pan-
metabolic model that contains all the reactions and genes
collected from a previous E. coli multi-strain study [17]
(see “Methods” section). We first identified 2485 core
metabolic reactions that are present in all 110 GEMs,
and 441 accessory reactions that are absent from at least
one GEM. Functional distribution of pan and core reac-
tions indicates that most accessory reactions are involved
in transport processes, carbon metabolism and cell enve-
lope biosynthesis (Fig. 2a), suggesting that these strains
are adapted to their own nutrient niches. Transporters in
bacteria are adapted to their environment in order to best
utilize the nutrients available [27]. Moreover, some acces-
sory reactions in the category of cell envelope biosynthesis
are involved in the synthesis of lipopolysaccharides (LPS),
molecules also known as endotoxins, that contribute to
the pathogenicity of E. coli strains. The toxic portion of
LPS, lipid A, induces a release of host proinflammatory
cytokines and causes infection within the host [28]. These
models illustrate potential variation in LPS components,
which could directly correlate with host inflammatory
state in IBD patients.
We specifically examined the distribution of reac-
tions in B2 and non-B2 strains. We investigated the
26 reactions that are unique to B2 strains, and iden-
tified three reactions that exist in more than 80%
of B2 strains: manganese ATP-binding cassette (ABC)
transporter, arabino-3-hexulose-6-phosphate isomerase,
and reversible dihydrolipoamide dehydrogenase (Fig. 2b).
Strains in both B2 and non-B2 groups are able to trans-
port manganese via permease, while only B2 strains are
able to transport manganese via ABC transporter. Knowl-
edge of the other two enzymes is limited, and are thus
potential experimental targets. In addition, three other
transport reactions involved in the uptake of phospho-
enolpyruvate, D-glycerate 2-phosphate, and D-glycerate
3-phosphate are also present in more than 30% of B2
strains. This is due to the presence of the pgtP gene,
originally found in Salmonella, which is responsible for
phosphoglycerate transport [29]. Thirteen reactions are
missing from all B2 models, but were later found to be
uncommon in non-B2 strains, as well. To further eluci-
date the differences in metabolic functions between B2
and non-B2 strains, we simulated growth of these strains
on a variety of nutrient sources.
Comparative analysis of GEMs highlights metabolic
capabilities unique to B2 E. coli strains
Growth simulation of GEMs predicted that strains in
the B2 group, including 52 isolates from IBD studies,
share similar metabolic capabilities (Fig. 3a), regardless
of the IBD status of their hosts. Growth simulations
were performed for 649 substrates under aerobic condi-
tions, as research has shown that aerobic respiration is
required for E. coli to colonize themouse intestine [30]. B2
strains isolated in IBD studies displayed distinct metabolic
capabilities compared to other InPEC strains, includ-
ing Enterotoxigenic E. coli, Enteropathogenic E. coli, and
Enteroaggregative E. coli, but are similar to ExPEC strains
in B2 groups such as Uropathogenic E. coli strains. This
result is interesting since a subset of AIEC and other
InPEC strains all colonize epithelial cells in the small
intestine [1, 31] and thus likely share a preferred microen-
vironment, yet they display distinct metabolic capabilities.
Specifically, B2 strains were predicted to be unable to
grow on certain substrates, including psicoselysine, fruc-
toselysine, meliobiose, cyanate, phenylpropanoate and
L-Xylulose (Table 1).
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Fig. 2 Reactions distribution in 110 GEMs. a Distribution of pan and core reactions in different systems for 110 E. colimodels. b Unique reactions in
models of B2 strains. Reactions present in more than 80% and 30% of B2 models are shown
We then investigated the most differentiating nutrient
sources between B2 and non-B2 strains: fructoselysine
and psicosylysine, also known as amadori products, that
are abundantly formed in heated food and decomposed by
microorganisms in the large intestine [32]. Further inves-
tigation using GEMs suggested that both the fructosely-
sine transporter and frl operon, including fructoselysine
6-kinase and fructoselysine 6-phosphate deglycase, are
missing from E. coli strains in phylogroup B2, resulting
in their inability to metabolize fructoselysine and psi-
coselysine. This result is consistent with experimental
data describing growth of mutant E. coli strains on fruc-
toselysine [33]. It is possible that B2 E. coli strains do
not use these substrates directly, but instead use their
derivatives produced by other organisms. Research has
shown that Intestinimonas AF211 and related bacteria
that are abundantly present in colonic samples are able to
convert amadori products into butyrate [34], a substrate
that could be metabolized by all E. coli strains in the B2
group, while 50% of the non-B2 strains failed to do so
(Fig. 3b). This could potentially explain the lack of degra-
dation enzymes for fructoselysine and psicoselysine in B2
strains: by dispensing these enzymes, B2 strains could rely
on neighboring bacteria to convert these substrates into
a more readily usable and potentially less sought after
product. Additionally, butyrate plays an important role
in maintaining intestinal homeostasis and has therapeutic
potential for IBD patients [35]. The elevated abundance of
B2 strains in IBD patients and their capability to metabo-
lize butyrate could potentially be related to the decreased
concentration of butyrate in feces of IBD patients [36] and
inflammation.
a b
c
Fig. 3 Simulated growth capabilities of 107 GEMs on various nutrient sources. a 107 strains are clustered by simulated growth capabilities on 143
differentiating nutrient sources. b Simulated growth on monosaccharides and their derivatives from mucus glycan. c Simulated growth on butyrate,
fructoselysine and psicoselysine
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Table 1 Growth substrates that differentiate E. coli strains in B2 phylogroup from other strains
Phylogroup B2 Other phylogroups
Growth Substrates AIEC IBD (%) Commensal IBD (%) ExPEC (%) InPEC (%) Commensal (%) Shigella (%)
Fructoselysine 0 3.2 0 90.9 69.2 87.5
Psicoselysine 0 3.2 0 90.9 69.5 87.5
Melibiose 4.6 6.5 33.3 81.8 57.7 100
L-Xylulose 4.6 6.5 33.3 45.5 69.2 12.5
Cyanate 4.6 6.5 33.3 90.9 65.4 0
Phenylpropanoate 4.6 6.5 33.3 90.91 65.4 12.5
Xanthosine 5’-phosphate 77.3 93.6 77.8 45.5 38.5 0
Xanthosine 77.3 93.6 77.8 45.5 38.5 0
Moreover, model simulations showed strains in phy-
logroup B2 differ from other strains in their abil-
ity to catabolize mucus monosaccharides. We exam-
ined the simulated growth capabilities of E. coli strains
on five monosaccharides and their derivatives that are
released from intestinal mucus glycan by commensals.
Simulated growth results suggest that 100% of the B2
strains can utilize all tested monosaccharides as their
sole carbon source, while only 65% of the strains from
other phylogroups can utilize all six substrates tested
(Fig. 3c).
Discussion
In this study, we delineated the specific metabolic capa-
bilities of E. coli B2 strains that are found to be prevalent
in IBD patients. Our study used pan-genome analysis of
metabolic genes and the growth capabilities they confer.
The study yielded three results: i) pan-genome analysis of
110 E. coli strains (including 53 isolates from IBD stud-
ies) revealed discriminating metabolic genes between B2
strains and other strains; ii) both comparative genomic
analysis and GEMs suggested that B2 strains have an
advantage in degrading and utilizing sugars derived from
mucus glycan, and iii) B2 strains display distinct metabolic
features, such as their inability to catabolize fructosely-
sine and psicoselysine, but instead are able to utilize the
derivatives produced by neighboring bacteria.
Pan-genome analysis of metabolic genes in 110 strains
revealed that B2 strains have distinct metabolic genes.
We identified genes that are unique to or more preva-
lent in B2 strains, including an extra copy of sucABCD
variant that encodes two important enzymes in the
TCA cycle. The importance and function of identified
genes need to be experimentally characterized in future
studies.
To evaluate the metabolic capabilities of these 110
strains on a systems level, we constructed draft models of
110 strains and examined their in silico growth capabili-
ties. B2 strains showed differentiating growth capabilities
on certain substrates (Table 1), including amadori prod-
ucts fructoselysine and psicoselysine, potentially because
they are able to utilize a derivative of amadori products -
butyrate, produced by their neighbouring bacteria.
Both pan-genome and GEM analysis showed that B2
strains have potential advantages that allow them to reside
within the human intestinal mucosa. In addition to exist-
ing TBP aldolases, GatY and KbaY, that are involved
in degrading mucus glycan component, B2 strains con-
tain four extra variants of TBP aldolases, suggesting a
potential advantage in utilizing intestinal mucus. Growth
simulation with GEMs also suggested that all B2 strains
are able to utilize all tested monosaccharides derived
from mucus glycan, while 35% of other strains failed
to do so.
Although we were able to identify common features
among B2 strains, we could not further differentiate sub-
groups within B2 strains (e.g. AIEC strains versus non-
AIEC strains, IBD isolates versus non-IBD isolates). To
separate subgroups of B2 strains, we explored diverse
datasets (e.g. a growth capability matrix and reaction con-
tent matrix generated fromGEMs, gene presence/absence
matrix generated from pan-genome) using various meth-
ods including feature selection method, supervised and
unsupervised clustering methods. Such attempts were not
entirely successful due to the following reasons: 1. AIEC
strains were shown to be a heterogeneous pathotype that
displays different genotypes, as shown in previous studies
[6]. Therefore, classification of AIEC strains based solely
on genomic information remains challenging. 2. Other
factors that affect IBD disease state were not taken into
account in this analysis, including environmental con-
ditions, host genetics and other microbial community
members. A broader approach that takes these factors
into consideration could provide valuable insight to the
role of E. coli strains in IBD patients. 3. Our study uti-
lized only genome sequences of E. coli strains, which only
delineates the genetic potentials, but not functional states
of these strains. Gene expression levels are unavailable
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for these strains, making it difficult for us to differentiate
subgroups of B2 strains (e.g. isolates from healthy con-
trols versus IBD patients). However, we hypothesize that
the genes identified here that are unique to B2 strains
may be upregulated and used during active IBD. This
hypothesis remains to be tested, however. Thus, while we
did not observe differences in genetic potential between
subgroups of B2 strains, gene expression data would likely
help differentiate IBD patient isolates from healthy control
isolates based on the different functional states they are in.
Conclusion
Taken together, these results suggest that the metabolic
capabilities of B2 strains vary from those of other strains,
enabling them to colonize intestinal mucosa. The results
from this study motivate a broad experimental assessment
of the ability of B2 E. coli strains to utilize different sub-
strates, and further investigations in if they confer growth
rate advantages under simulated intestinal conditions. If
these strain-specific growth advantages are confirmed in
vitro, the nutritional effects on E. coli B2 pathophysiology
in IBD patients should be rigorously evaluated.
Methods
Bacterial genome sequences
We collected 76 genome sequences (including 39 AIEC
strains) from various publications [6, 10, 11, 37–40]. We
recorded their associatedmetadata: IBD status of originat-
ing patient, anatomic site of collection, serotype, phylo-
type, and other relevant information where available (see
Additional file 1: Table S1). For comparison, we utilized
genome sequences of 57 other E. coli strains that span
various pathotypes as well as commensal strains, most of
which are collected from a previous multi-strain E. coli
study [17]. The quality of the genome sequences varied
since they originated from multiple publications. There-
fore, we calculated N50 scores of each genome sequence,
and only performed analysis on 110 E. coli strains (includ-
ing 53 IBD-associated strains) that have a N50 score
greater than 200,000.
Pan-genome construction and analysis
We first annotated 110 E. coli genome sequences and
aligned them against each other using CD-HIT [19] with
the cutoff for “align average” set to 80%, so that genes with
80% or more sequence similarity are grouped together.
We utilized the PATRIC database [41] to extract our
sequences and gene calls. All annotations in this resource
are called using the same pipeline that consists of assem-
bly with SPADES [42] and annotation with RAST [43].
RAST annotation has also provided EC numbers that
allow us to identify metabolic genes. With the alignment,
we created a binary matrix that describes the presence
or absence of each gene in the strains. We extracted only
metabolic genes with enzyme commision numbers. We
then performed feature selection using SelectKBest func-
tion from the scikit-learn package [20] to select the top
features that differentiate B2 and non-B2 strains.
Analysis of genes involved in mucus degradation
Genes that are involved in degrading the five monosac-
charides derived from mucus were primarily identified
from a previous study by Ravcheev and Thiele [24]. Gene
sequences of the identified genes were collected from the
supplementary file of the aforementioned paper. Addi-
tional genes involved in galactose metabolism were iden-
tified and added based on gene annotation and known
pathways. Genome sequences of 110 strains were blasted
against 48 identified genes with a threshold of 80%
sequence similarity using BLAST [44].
Protein structural analysis of TBP aldolase
To inspect the possible functions of the additional four
predicted class II TBP aldolases in B2 strains, we car-
ried out a comparative analysis of each enzyme’s pre-
dicted protein structure. Homologymodels were obtained
from two modeling pipelines (SWISS-MODEL [45] and
I-TASSER [46]) in order to compare results from differ-
ent modeling approaches. Models were compared to the
only crystallized structure of TBP aldolase (PDB ID: 1GVF
[25]) and a structure of FBP aldolase (PDB ID: 1B57 [26]),
which are both bound to a substrate analog of the nat-
ural substrate of TBP as well as the cations required for
catalysis. Important residues for catalysis were gathered
fromHall et al. [25] for comparison in all models. The two
sets of homology models were found to be very similar in
overall structure and location of these important residues,
and as a result the reported results do not differ between
the generated models. For visualization, VMD [47] was
used along with the MultiSeq plugin [48] to structurally
superimpose all models.
Draft model reconstruction of other E. coli strains
We first created an E. coli pan model that combines all
the genes, reactions, and metabolites in the 55 E. coli
models reconstructed by Monk et al. [17]. In addition,
in order to incorporate any novel metabolic functions
in the 110 strains that are absent from the previously-
built E. coli models, we identified 340 metabolic genes
in the constructed pan-genome that are absent from the
previously studied 55 strains. However, the majority of
the 340 genes are variants of existing genes, and only
96 genes may encode new functions. For these 96 genes,
we utilized Uniprot [49] database to identify associated
reactions, with the following criteria to select the reac-
tions to include: 1) Not involved in DNA/RNA modifica-
tion, as suggested by the established GEM reconstruction
protocol [50]; 2) experimentally proven to be present in E.
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coli; 3) have a defined reaction with specificity; 4) do not
duplicate with existing reactions in the 55 GEMs. In the
end, we only identified five new metabolic reactions that
fulfill all above requirements (see Additional file 1: Table
S3), mainly because these strains are not as well studied
compared to the previous 55 strains, and little experimen-
tal evidence was found for the majority of the investigated
metabolic functions. We then added these new reactions
to the pan model created from the previous 55 models. To
create strain-specific draft models, we mapped the 110 E.
coli genome sequences to all the genes in the pan model
using BLAST [44], and set a homology threshold of 80%
for a gene to be considered present in the strain. Themiss-
ing genes and their correlated reactions and metabolites
in each strain were removed from the pan model to create
strain-specific draft models.
In silico growth simulations
Growth simulation for E. coli draft models were per-
formed using COBRApy [51].We usedM9minimal media
with the lower bound of exchange reactions for the follow-
ing substrate set to -1000: Ca2+, Cl−, CO2, Co2+, Cu2+,
Fe2+, Fe3+, H+, H2O, K+, Mg2+, Mn2+, MoO4 2, Na+,
Ni2+, SeO42−, SeO32+, and Zn2+. Another essential sub-
strate is cob(I)alamin, for which the exchange reaction has
a lower bound of -0.01. In addition, the default carbon
source is glucose with default lower bound set to be -20,
while the default nitrogen, sulfur and phosphate sources
are NH4−, SO42, HPO42 with the lower bounds all set
to be -1000. We evaluated if sole carbon, nitrogen, sulfur
or phosphate substrates supported growth by setting the
lower bound of the exchange reaction of the default sub-
strate to 0, and added sole substrates by setting the lower
bound of exchange reaction to -10. We simulated growth
under aerobic conditions with the lower bound of the oxy-
gen exchange reaction set to -20. If the simulated growth
rate is greater than 1% of the original growth rate (when all
default nutrient sources are used), the strain is considered
to be able to grow under the tested condition.
Among all 110 strains tested, three draft GEMs were
not able to simulate growth on the majority of the sub-
strates, potentially due to auxotrophy: E. coli str K-12
substr DH10B, E. coli O111 H-str 11128, E. coli NA114.
These strains were therefore excluded from the following
growth capability analysis.
We used SelectKBest function in scikit-learn package
[20] to select the top 10 growth substrates that differen-
tiate B2 and non-B2 strains, with the score function set
to “f_classif”. We then summarized the percentage strains
in each pathotype that could utilize these substrates in
Table 1. Note that in Table 1 we classified pathotypes to
B2 group and non-B2 group, but with a few exceptions in
both groups: i.e. non-B2 strains in the ExPEC group and
B2 strains in the commensal group.
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